UPDATE – Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference
Spero Therapeutics (Nasdaq: SPRO), a clinical-stage biopharmaceutical company specializing in rare diseases and multi-drug resistant bacterial infections treatments, has announced its participation in the TD Cowen 45th Annual Health Care Conference.
The conference will take place in Boston from March 3rd to 5th, 2025, where Esther Rajavelu, Spero's Interim President and CEO, will present and be available for one-on-one meetings. Interested parties can access the presentation webcast through Spero Therapeutics' website under the 'Events and Presentations' section, with a replay available after the event.
Spero Therapeutics (Nasdaq: SPRO), un'azienda biofarmaceutica in fase clinica specializzata nel trattamento delle malattie rare e delle infezioni batteriche multi-resistenti, ha annunciato la sua partecipazione alla 45ª Conferenza Annuale sulla Salute di TD Cowen.
La conferenza si terrà a Boston dal 3 al 5 marzo 2025, dove Esther Rajavelu, Presidente e CEO ad interim di Spero, presenterà e sarà disponibile per incontri individuali. Le parti interessate possono accedere alla trasmissione in diretta della presentazione attraverso il sito web di Spero Therapeutics nella sezione 'Eventi e Presentazioni', con una registrazione disponibile dopo l'evento.
Spero Therapeutics (Nasdaq: SPRO), una empresa biofarmacéutica en etapa clínica especializada en el tratamiento de enfermedades raras e infecciones bacterianas multirresistentes, ha anunciado su participación en la 45ª Conferencia Anual de Salud de TD Cowen.
La conferencia se llevará a cabo en Boston del 3 al 5 de marzo de 2025, donde Esther Rajavelu, Presidenta y CEO interina de Spero, presentará y estará disponible para reuniones individuales. Las partes interesadas pueden acceder a la transmisión en vivo de la presentación a través del sitio web de Spero Therapeutics en la sección 'Eventos y Presentaciones', con una repetición disponible después del evento.
Spero Therapeutics (Nasdaq: SPRO), 희귀 질환 및 다제내성 박테리아 감염 치료를 전문으로 하는 임상 단계의 생명공학 회사가 TD Cowen 제45회 연례 건강 관리 회의에 참여한다고 발표했습니다.
회의는 2025년 3월 3일부터 5일까지 보스턴에서 열리며, Esther Rajavelu Spero의 임시 회장 겸 CEO가 발표하고 일대일 미팅을 위해 참석할 예정입니다. 관심 있는 분들은 Spero Therapeutics 웹사이트의 '이벤트 및 발표' 섹션을 통해 발표 웹캐스트에 접근할 수 있으며, 이벤트 후 다시 볼 수 있습니다.
Spero Therapeutics (Nasdaq: SPRO), une entreprise biopharmaceutique en phase clinique spécialisée dans le traitement des maladies rares et des infections bactériennes multirésistantes, a annoncé sa participation à la 45ème Conférence Annuelle sur la Santé de TD Cowen.
La conférence se déroulera à Boston du 3 au 5 mars 2025, où Esther Rajavelu, Présidente et CEO par intérim de Spero, présentera et sera disponible pour des réunions individuelles. Les parties intéressées peuvent accéder à la diffusion en direct de la présentation via le site web de Spero Therapeutics dans la section 'Événements et Présentations', avec une rediffusion disponible après l'événement.
Spero Therapeutics (Nasdaq: SPRO), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Behandlung seltener Krankheiten und multiresistenter bakterieller Infektionen spezialisiert hat, hat seine Teilnahme an der 45. jährlichen Gesundheitskonferenz von TD Cowen angekündigt.
Die Konferenz findet vom 3. bis 5. März 2025 in Boston statt, wo Esther Rajavelu, Interim-Präsidentin und CEO von Spero, präsentieren und für persönliche Gespräche zur Verfügung stehen wird. Interessierte Parteien können über die Website von Spero Therapeutics im Abschnitt 'Veranstaltungen und Präsentationen' auf den Live-Stream der Präsentation zugreifen, mit einer Wiederholung, die nach der Veranstaltung verfügbar ist.
- None.
- None.
CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Esther Rajavelu, Spero’s Interim President and Chief Executive Officer, management will present and will be available for one-on-one meetings at the TD Cowen 45th Annual Health Care Conference being held in Boston, March 3rd – 5th, 2025. Details are as follows:
| TD Cowen 45th Annual Health Care Conference | |
| Company presentation: | Tuesday March 4, 2025 |
| Time: | 3:10 PM ET |
To request a meeting or for more details about the conferences please reach out to your institutional contact.
The webcast may also be accessed through Spero Therapeutics’ website (www.sperotherapeutics.com) on the “Events and Presentations” page under the “Connect” tab. A replay will be available on the website following the conclusion of the event.
About Spero Therapeutics
Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset, clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and MDR bacterial infections.
For more information, visit https://sperotherapeutics.com.
Investor Relations Contact:
Shai Biran, PhD
Spero Therapeutics
IR@Sperotherapeutics.com
Media Inquiries:
media@sperotherapeutics.com
FAQ
When and where is Spero Therapeutics (SPRO) presenting at the TD Cowen Healthcare Conference 2025?
How can investors access Spero Therapeutics' (SPRO) TD Cowen conference presentation?
What is Spero Therapeutics' (SPRO) current business focus?
Who will represent Spero Therapeutics (SPRO) at the TD Cowen Healthcare Conference?
